(NYSE:IQV) today announced that Ferring
Pharmaceuticals, a global leader in reproductive health, women’s
health and other medical therapies, has selected IQVIA Technologies’ Orchestrated
Customer Engagement (OCE) platform for global deployment across more
than 50 markets.
“We are pleased to be working with IQVIA on this project,” said Vincent
Turgis, Global CIO, Ferring Pharmaceuticals. “OCE will enable us to
streamline processes while developing strong customer relationships as
we better anticipate and respond to market changes.”
IQVIA Technologies’ OCE for advanced customer engagement breaks down
silos by seamlessly connecting sales, account management, and other
functions to enhance the customer experience, strengthen relationships,
and drive performance. OCE is built on best-in-class industry platforms,
including Salesforce, Amazon Web Services, MuleSoft, Heroku, and Box.
With unique capabilities, such as predictive analytics and machine
learning, OCE provides an intuitive consumer-grade user experience,
AI-enabled recommendations, seamless integration with other data and
applications to drive better decision-making.
“We are confident that OCE will transform Ferring’s customer
interactions by optimizing performance,” said Tal Rosenberg, senior vice
president, Global Technology Solutions for IQVIA Technologies. “OCE is
part of an integrated commercial ecosystem that enables clients to
manage the process of customer engagement from one end to the other.
This platform will harmonize customer interactions, which leads to
enhanced trust and optimized performance with clients.”
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit www.iqvia.com.